Chemotherapy for Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00090727|
Recruitment Status : Unknown
Verified April 2005 by Novacea.
Recruitment status was: Active, not recruiting
First Posted : September 6, 2004
Last Update Posted : November 2, 2006
The purposes of this study are to determine:
- the largest dose of AQ4N that can be safely given once a week for three weeks out of a 4 week cycle
- the side effects of AQ4N when given on the above schedule
- how much AQ4N is in the blood and urine at specific times after administration and how the body get rids of AQ4N
- if AQ4N helps treat cancer
|Condition or disease||Intervention/treatment||Phase|
|Solid Malignancies Non-Hodgkin's Lymphoma||Drug: AQ4N||Phase 1|
This study is for people who have advanced cancer for which standard chemotherapy did not work or for which there are no reliably, effective treatments.
AQ4N is an experimental chemotherapy that is thought to target tumor areas with low oxygen content and low blood supply; tumor areas that are usually the most resistant to standard chemotherapy and radiation treatment. AQ4N may be beneficial in cancer treatment by interfering with a protein that is required for cells to grow and divide, causing tumors to die or to delay their growth.
All patients in this study will receive AQ4N. The dose will be increased for each new patient or group of patients until the maximum tolerated dose is reached.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||45 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase 1, Open-Label, Dose-Escalation Study of AQ4N Administered Intravenously in Patients With Advanced Malignancies|
|Study Start Date :||August 2004|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00090727
|United States, New York|
|Weiler Hospital of Albert Einstein College of Medicine|
|Bronx, New York, United States, 10461|
|United States, Texas|
|Cancer Therapy & Research Center / Institute for Drug Development|
|San Antonio, Texas, United States, 78229|